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Conclusion: Proton-beam grids with 3 mm beam elements 
produce dose distributions in water for which the grid pattern 
is preserved down to large depths. PBGT could be carried out 
at proton therapy centers, equipped with spot-scanning 
possibilities, using existing tools. However, smaller beams 
than those currently available could be advantageous for 
biological reasons. With PBGT, it is also possible to create a 
more uniform target dose than what has been possible to 
produce with photon-beam grids. We anticipate that PBGT 
could be a useful technique to reduce both short- and long-
term side effects after radiotherapy. 
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Purpose or Objective: Currently, various MR-guided 
radiotherapy systems are being developed and clinically 
implemented. For conventional radiotherapy, Electronic 
Portal Imaging Devices (EPIDs) are frequently used for in vivo 
dose verification. The high complexity of online treatment 
adaptation makes independent dosimetric verification in the 
Elekta MR-linac combination indispensable. One of the 
challenges for MR-linac portal dosimetry is the presence of 
the MRI housing between the patient and the EPID. 
The purpose of this study was to adapt our previously 
developed back-projection algorithm for the presence of the 
MRI scanner. 
 
Material and Methods: Three steps have been added to our 
current EPID dosimetry back-projection model to account for 
the presence of the MRI scanner: i) subtraction of scatter 
from the MRI to the EPID, ii) correction for the MRI 
attenuation, iii) compensation for changes in the beam 
spectrum. The calibration of the algorithm needs a set of 
commissioning data (from EPID and ionization chamber, both 
with and without the MRI) to determine the parameters for 
the back-projection method. 
An aluminum block of 12 cm thickness at 15 cm distance from 
the EPID was used to approximate the effects of the MRI 
scanner. Measurements were performed using a 6MV photon 
beam of a conventional SL20i linear accelerator (Elekta AB, 
Stockholm, Sweden) at 0° gantry. 
58 IMRT fields of 11 plans (H&N, lung, prostate and rectum) 
were delivered to a 20 cm polystyrene slab phantom and 
portal images were acquired with the aluminum plate in 
place. For independent comparison with our conventional 
method the same fields were delivered without the aluminum 
plate. The EPID images were converted to dose, corrected for 
the presence of the aluminum plate, back-projected into the 
phantom and compared to the planned dose distribution 
using a 2-D gamma evaluation (3%, 3 mm). 
 
Results: The γ_mean averaged over the 58 IMRT fields was 
0.39±0.11, the γ_1% was 1.05±0.30 and the %_γ≤1 was 
95.7±5.3. The dose difference at the isocenter was -0.7±2.2 
cGy. These results are in close agreement with the 
performance of our algorithm for the conventional linac 




Conclusion: Our EPID dosimetry back projection algorithm 
was successfully adapted for the presence of an attenuating 
medium between phantom (or patient) and EPID. 
Experiments using a 12 cm aluminum plate (approximating 
the MR-linac geometry) showed excellent agreement 
between planned and EPID reconstructed dose distributions. 
This result is an essential step towards an accurate, 
independent, and potentially fast field-by-field IMRT portal 
dosimetry based verification tool for the MR-linac. 
Part of this research was sponsored by Elekta AB.  
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Purpose or Objective: Hyperthermia is a (neo)adjuvant 
treatment modality that increases the effectiveness of 
radiotherapy or chemotherapy by heating the tumour area to 
41–43 °C. Loco-regional hyperthermia is delivered using 
phased array systems with individually controlled antennae. 
Hyperthermia treatment planning is necessary to determine 
the phase and amplitude settings for the individual antennae 
that result in the optimal temperature distribution. Current 
treatment planning systems are accurate for solid tissues but 
ignore the specific properties of the urinary bladder and its 
contents, which limits their accuracy in the pelvic region. 
This may have clinical implications for such treatment sites 
as the rectum, the cervix uteri, and the bladder itself.  
